The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours.
Floor J E LubbermanWinette T A van der GraafLei XuAdriaan CletonGeorge D DemetriHans GelderblomNielka P van ErpPublished in: British journal of clinical pharmacology (2019)
Our study shows that major gastrectomy did not influence plasma exposure of regorafenib and metabolites. In addition, no difference in PFS between the subgroups was seen.